In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.

A new study suggests that targeting the protein alpha-synuclein could be a possible new target for treating melanoma.

In one study, once-daily danuglipron resulted in one patient who experienced drug-related elevated liver enzymes.

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the ...

Panelists discuss how an 18-month retrospective claims analysis evaluated ruxolitinib's real-world effectiveness in atopic ...

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability ...

The end of federal diversity, equity and inclusion programs in the federal government may have a ripple effect on social ...

Republicans are aiming for major reductions in federal spending, and Medicaid seems a likely target. But the politics of ...

The CEOs of CVS Health and UnitedHealth Group praised pharmacy benefit managers and promised transparency during investor ...

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

Lexeo Therapeutics’ gene therapy provides a healthy version of the frataxin gene, which is critical for energy production in ...

United Health Foundation, the charitable branch of UnitedHealth Group, awarded more than $7 million in grants to ...